Glutamate transporter EAAT2 splice variants occur not only in ALS, but also in AD and controls

Neurology

Volumn 55, Issue 8, 2000, Pages 1082-1088

  Honig, L S ^a,c   Chambliss, D D ^a   Bigio, E H ^a   Carroll, S L ^b   Elliott, J L ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b University of Alabama at Birmingham   (United States)

^c Columbia University College of Physicians and Surgeons ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; EXCITATORY AMINO ACID; GLUTAMIC ACID; MESSENGER RNA;

ALTERNATIVE RNA SPLICING; ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DEGENERATIVE DISEASE; DEMENTIA; HUMAN; HUMAN TISSUE; MOTOR NEURON DISEASE; NEUROLOGIC DISEASE; NEUROPATHOLOGY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL;

EID: 0034711151     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.55.8.1082     Document Type: Article

References (33)

1. Do posttranslational modifications of CuZn SOD lead to sporadic amyotrophic lateral sclerosis?
2. ALS-linked SOD1 mutant G85R mediates damage to astrocytes and promotes rapidly progressive disease with SOD1-containing inclusions
3. From Charcot to SOD1: Mechanisms of selective motor neuron death in ALS
4. Amyotrophic lateral sclerosis
5. Abnormal excitatory amino acid metabolism in amyotrophic lateral sclerosis
6. Amyotrophic lateral sclerosis: Amino acid levels in plasma and cerebrospinal fluid
7. Fasting plasma and CSF amino acid levels in amyotrophic lateral sclerosis: A sub-type analysis
8. Amino acids acting as transmitters in amyotrophic lateral sclerosis (ALS)
9. Altered glutamatergic mechanisms and selective motor neuron degeneration in amyotrophic lateral sclerosis: Possible role of glycine
10. Glutamate dysfunction and selective motor neuron degeneration in amyotrophic lateral sclerosis: A hypothesis
11. Excitotoxicity hypothesis
12. Excitotoxic mechanisms in the pathogenesis of amyotrophic lateral sclerosis
13. Excitotoxicity and neurodegeneration in amyotrophic lateral sclerosis
14. Neurotoxic mechanisms of degeneration in motor neuron diseases
15. Chronic inhibition of glutamate uptake produces a model of slow neurotoxicity
16. Mechanism of selective motor neuronal death after exposure of spinal cord to glutamate: Involvement of glutamate-induced nitric oxide in motor neuron toxicity and nonmotor neuron protection
17. Glutamate transporter gene expression in amyotrophic lateral sclerosis motor cortex
18. Selective loss of glial glutamate transporter GLT-1 in amyotrophic lateral sclerosis
19. Decreased glutamate transport by the brain and spinal cord in amyotrophic lateral sclerosis
20. Localization of neuronal and glial glutamate transporters
21. SOD1 mutants linked to amyotrophic lateral sclerosis selectively inactivate a glial glutamate transporter
22. Aberrant RNA processing in a neurodegenerative disease: The cause for absent EAAT2, a glutamate transporter, in amyotrophic lateral sclerosis
23. Aberrant RNA processing in a neurodegenerative disease: The cause for absent EAAT2, a glutamate transporter, in amyotrophic lateral sclerosis
24. Identification of alternative splicing forms of GLT-1 mRNA in the spinal cord of amyotrophic lateral sclerosis patients
25. Alternative splicing of the glutamate transporter EAAT2 (GLT-1)
26. Splicing of the glutamate transporter EAAT2: A candidate gene of amyotrophic lateral sclerosis
27. Glutamate transporter EAAT-2 splice variant are not specific to ALS but are present in normal and Alzheimer disease brains
28. The RNA of the glutamate transporter EAAT2 is variably spliced in amyotrophic lateral sclerosis and normal individuals
29. Clinically and neuropathologically distinct form of dementia in the elderly
30. The Lewy body variant of Alzheimer's disease: A clinical and pathologic entity
31. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease
32. Evolution of neuronal changes in the course of Alzheimer's disease
33. Genomic organization of the human excitatory amino acid transporter gene GLT-1